
Pig Kidney Transplants Are Now in Human Trials. Here Is What EXPAND and Its Rivals Actually Have to Prove
Dr. Dereck Mush, MD, MBAeGenesis is a biotechnology company that uses genome engineering to develop pig organs designed to be compatible with human transplant recipients.
Checked 14 November 2026. Source
eGenesis was founded in 2015 and is based in Cambridge, Massachusetts. Its lead candidate is a donor kidney from a pig with three classes of genetic edits: removing genes linked to immediate rejection, adding seven human genes that help regulate immune and clotting responses, and inactivating viruses carried in the pig genome. In March 2024 a team at Massachusetts General Hospital performed the first transplant of an eGenesis kidney into a living patient under FDA expanded access. The company also has programs in acute liver failure and heart transplant. It raised a $191 million Series D in September 2024 led by Lux Capital.
Leadership as of 14 November 2026.
President and CEO

Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBARelated companies